Federal Project Grant Award Summary

The Defense Health Agency awarded a $311,141 Project Grant to The Johns Hopkins University effective September 1, 2026 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). The research project, titled "Leveraging Germline and Somatic ATM Status in Patients with Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma," will be conducted at the Baltimore, Maryland location. This three-year initiative investigates the genetic and molecular characteristics of pancreatic neoplasms and adenocarcinomas by examining ATM (Ataxia Telangiectasia Mutated) gene status in both inherited and acquired tumor mutations to advance understanding of pancreatic cancer biology and inform precision medicine approaches.

The research aligns with the Defense Health Agency's strategic focus on biomedical research addressing conditions affecting the military population and the broader American public. As a premier research institution with extensive experience in federal medical research initiatives, Johns Hopkins will deliver investigative findings and scientific outcomes designed to contribute to improved diagnostic and therapeutic strategies for pancreatic malignancies under the Military Medical Research and Development program's three- to four-year award cycle.